Dose-finding and Pharmacokinetic Trial of Orally Administered D-24851 to Patients With Solid Tumors

Trial Profile

Dose-finding and Pharmacokinetic Trial of Orally Administered D-24851 to Patients With Solid Tumors

Completed
Phase of Trial: Phase I

Latest Information Update: 10 Oct 2013

At a glance

  • Drugs Indibulin (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors ZIOPHARM Oncology
  • Most Recent Events

    • 19 Jun 2009 Actual number of patients (47), lead investigator (Lewis J) added as reported by ClinicalTrials.gov.
    • 19 Jun 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 04 Jun 2007 Interim results were presented at the 2007 American Society of Clinical Oncology (ASCO) meeting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top